Lynn Anne Bristol

Array ( [id] => 16649991 [patent_doc_number] => 10927154 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Multi-specific polypeptide useful for localized tumor immunomodulation [patent_app_type] => utility [patent_app_number] => 15/111153 [patent_app_country] => US [patent_app_date] => 2015-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 14 [patent_no_of_words] => 25874 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15111153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10240464 [patent_doc_number] => 20150125459 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-07 [patent_title] => 'APELIN PEPTIDES, ANTIBODIES THERETO, AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/593099 [patent_app_country] => US [patent_app_date] => 2015-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 27712 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14593099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11507347 [patent_doc_number] => 09598493 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-21 [patent_title] => 'Human monoclonal antibodies against CD25' [patent_app_type] => utility [patent_app_number] => 14/592558 [patent_app_country] => US [patent_app_date] => 2015-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 17 [patent_no_of_words] => 30093 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 229 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14592558 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10219456 [patent_doc_number] => 20150104449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-16 [patent_title] => 'Variant Immunoglobulins with Improved Manufacturability' [patent_app_type] => utility [patent_app_number] => 14/589066 [patent_app_country] => US [patent_app_date] => 2015-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20158 [patent_no_of_claims] => 58 [patent_no_of_ind_claims] => 25 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14589066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13763553 [patent_doc_number] => 10174111 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-08 [patent_title] => Therapeutic drug for malignant tumors [patent_app_type] => utility [patent_app_number] => 15/108242 [patent_app_country] => US [patent_app_date] => 2014-12-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 57 [patent_no_of_words] => 39213 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 305 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15108242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10614895 [patent_doc_number] => 09334330 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-10 [patent_title] => 'Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers' [patent_app_type] => utility [patent_app_number] => 14/581048 [patent_app_country] => US [patent_app_date] => 2014-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 19 [patent_no_of_words] => 20250 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14581048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10219390 [patent_doc_number] => 20150104383 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-16 [patent_title] => 'SELENOCYSTEINE MEDIATED HYBRID ANTIBODY MOLECULES' [patent_app_type] => utility [patent_app_number] => 14/579180 [patent_app_country] => US [patent_app_date] => 2014-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 13652 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14579180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10347556 [patent_doc_number] => 20150232561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'METHOD FOR SELECTION AND PRODUCTION OF TAILOR-MADE HIGHLY SELECTIVE AND MULTI-SPECIFIC TARGETING ENTITIES CONTAINING AT LEAST TWO DIFFERENT BINDING ENTITIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/579218 [patent_app_country] => US [patent_app_date] => 2014-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24268 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14579218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10347555 [patent_doc_number] => 20150232560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/579165 [patent_app_country] => US [patent_app_date] => 2014-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 50379 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14579165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11122043 [patent_doc_number] => 20160319018 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-03 [patent_title] => 'CANINIZED MURINE ANTIBODIES TO HUMAN PD-1' [patent_app_type] => utility [patent_app_number] => 15/104838 [patent_app_country] => US [patent_app_date] => 2014-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 16360 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15104838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11114955 [patent_doc_number] => 20160311927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'MONOCLONAL ANTI-TK1 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/105999 [patent_app_country] => US [patent_app_date] => 2014-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 14922 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15105999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10608151 [patent_doc_number] => 09328173 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-03 [patent_title] => 'Multifunctional antibodies binding to EGFR and MET' [patent_app_type] => utility [patent_app_number] => 14/573373 [patent_app_country] => US [patent_app_date] => 2014-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 23093 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14573373 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10306535 [patent_doc_number] => 20150191535 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-09 [patent_title] => 'BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG2 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/571091 [patent_app_country] => US [patent_app_date] => 2014-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 27356 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14571091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10267196 [patent_doc_number] => 20150152192 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-04 [patent_title] => 'ANTI-C-MET/ANTI-ANG2 BISPECIFIC ANTIBODY' [patent_app_type] => utility [patent_app_number] => 14/556911 [patent_app_country] => US [patent_app_date] => 2014-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 25310 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14556911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10281673 [patent_doc_number] => 20150166670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-18 [patent_title] => 'MULTISPECIFIC ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/551957 [patent_app_country] => US [patent_app_date] => 2014-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 21315 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14551957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11277076 [patent_doc_number] => 09493552 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-15 [patent_title] => 'Therapeutic biologic for treatment of hepatocellular carcinoma' [patent_app_type] => utility [patent_app_number] => 14/539577 [patent_app_country] => US [patent_app_date] => 2014-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 28 [patent_no_of_words] => 17615 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14539577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11083800 [patent_doc_number] => 20160280765 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-29 [patent_title] => 'HUMAN IGG1 DERIVED ANTIBODY WITH PRO-APOPTOTIC ACTIVITY' [patent_app_type] => utility [patent_app_number] => 15/036118 [patent_app_country] => US [patent_app_date] => 2014-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 10329 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15036118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9901016 [patent_doc_number] => 20150056216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-26 [patent_title] => 'ANTIBODY COMBINATIONS AND USE OF SAME FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 14/536754 [patent_app_country] => US [patent_app_date] => 2014-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 11358 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14536754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10248644 [patent_doc_number] => 20150133640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-14 [patent_title] => 'Production of T cell retargeting hetero-dimeric immunoglobulins' [patent_app_type] => utility [patent_app_number] => 14/532923 [patent_app_country] => US [patent_app_date] => 2014-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 66 [patent_figures_cnt] => 66 [patent_no_of_words] => 53728 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14532923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13106881 [patent_doc_number] => 10072073 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-11 [patent_title] => Glycans as functional cancer targets and antibodies thereto [patent_app_type] => utility [patent_app_number] => 15/033568 [patent_app_country] => US [patent_app_date] => 2014-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 37 [patent_no_of_words] => 21588 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15033568 [rel_patent_id] =>[rel_patent_doc_number] =>)